Case Study: Blueprint Medicines achieves 35% efficiency gains and global reporting compliance with ArisGlobal LifeSphere

High-Growth, High-Volume Biotech Embraces High Efficiency and Accuracy with LifeSphere The Blueprint Medicines Story

Blueprint Medicines, a fast-growing precision-medicine biotech, faced scaling challenges from manual pharmacovigilance processes, vendor silos, and demanding multinational reporting obligations. To meet aggressive timelines without adding headcount, Blueprint selected ArisGlobal’s LifeSphere solutions, including LifeSphere Intake and Triage (LSIT) and LifeSphere Multivigilance (LSMV), to replace fragmented workflows and improve global gateway connectivity.

ArisGlobal implemented the LifeSphere suite (with additional onboarding of LifeSphere Signal and Risk Management, LSSRM), delivering end-to-end workflow visibility, automated reporting and China FDA gateway connectivity. The solution improved efficiency by more than 35%, enhanced compliance and accuracy, supported high-volume reporting at scale, and gave Blueprint the seamless scalability and regulatory monitoring needed for continued growth.

Blueprint Medicines

Anand Ananthakrishnan

Senior Director of Drug Safety and Pharmacovigilance